Considerations on Thrombotic Events Following Administration of the OXford-AstraZeneca COVID-19 Vaccine in Europe, 7 April 2021
Abstract
The Pan American Health Organization (PAHO) has issued this communiqué in response to the information circulating about potential risks associated with use of the COVID-19 vaccine developed by AstraZeneca and Oxford University, considering the reports of events in European countries. This communiqué offers an overview of the adverse effects following the administration of the Oxford–AstraZeneca COVID-19 vaccine notified in Europe, and of the recommendations issued by the World Health Organization, the European Medicines Agency, and other national regulatory authorities in that respect. In addition, it includes the recommendations of the Pan American Health Organization in consideration of the information and the evidence available.
Subject
Collections
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO
Related items
Showing items related by title, author, creator and subject.
-
SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil
Rodrigues Campos, Karoline; Tavares Sacchi, Cláudio; Abbud, Adriano; Caterino-de-Araujo, Adele (2021-09-15)[ABSTRACT]. COVID-19 vaccination began in São Paulo, Brazil in January 2021, first targeting healthcare workers (HCWs) and the elderly, using the CoronaVac vaccine (Sinovac/Butantan) and subsequently the Oxford/AstraZeneca ... -
Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina
Taborda R., Alejandra; Murillo, Diego Alejandro; Moreno L., Carolina; Taborda R., Paula Andrea; Fuquen, Marcela; Díaz, Paula Andrea; Londoño, Darío (2022-01-11)[RESUMEN]. Objetivo. Estimar el impacto presupuestal de la vacunación contra COVID-19 en seis países de América Latina: Argentina, Brasil, Chile, Colombia, México y Perú, durante el periodo 2021-2022. Métodos. Se evaluaron ... -
Documento de referência sobre a vacina AZD1222 contra COVID-19 desenvolvida pela Universidade de Oxford e pela AstraZeneca, 1 de março de 2021
Organização Pan-Americana da Saúde; Representação da OPAS/OMS no Brasil (Brasília, D.F., OPAS, 2021-07-26)Este documento de referência foi preparado pelo Grupo de Trabalho sobre Vacinas contra COVID-19 do Grupo Consultivo Estratégico de Especialistas em Imunização (SAGE) para orientar as discussões do SAGE em sua reunião ...